Menu
X
image 9 months ago

Yescarta Sites

Yescarta Sites Yescarta, a revolutionary CD19-targeted CAR-T cell therapy, has emerged as a promising treatment option for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Thi...

image 9 months ago

Yescarta Second Line DLBCL

Yescarta Second Line DLBCL On April 1, 2024, the US Food and Drug Administration (FDA) granted approval to Kite, a Gilead Sciences subsidiary, for Yescarta (Axicabtagene Ciloleucel), a CAR-T cell t...

image 9 months ago

Yescarta List Price

Yescarta List Price Cancer treatment has come a long way, and one of the most promising advancements in recent years is the development of CAR-T cell therapy. Yescarta, also known as “奕凯达&...

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.